Rakuten Aspyrian Announces Name Change to Rakuten Medical

On March 1, 2019 Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, reported that it has changed its name to Rakuten Medical, Inc (Press release, Rakuten Aspyrian, MAR 1, 2019, View Source/2019/02/28/rakuten-aspyrian-announces-name-change-to-rakuten-medical/" target="_blank" title="View Source/2019/02/28/rakuten-aspyrian-announces-name-change-to-rakuten-medical/" rel="nofollow">View Source [SID1234533855]). This name more closely reflects the company’s corporate purpose of creating a global biotechnology company integrating research and development with commercial operations in order to develop therapeutics that improve cancer patient outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are aiming to deliver PIT platform to as many cancer patients and as early as possible worldwide. Our new name that becomes effective today, Rakuten Medical, better aligns with our goal of developing a global brand that resonates within the pharmaceutical and medical device industries," said Mickey Mikitani, chairman and CEO of Rakuten Medical. "Despite our name change, our mission of ‘Conquering cancer, For life’ will not change. We are stronger today than ever before as we continue building the organization necessary to conquer cancer by developing innovative cancer treatments."

For more information, visit View Source